Mark Avigan

5.3k total citations · 1 hit paper
71 papers, 3.5k citations indexed

About

Mark Avigan is a scholar working on Epidemiology, Pharmacology and Hepatology. According to data from OpenAlex, Mark Avigan has authored 71 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Epidemiology, 23 papers in Pharmacology and 18 papers in Hepatology. Recurrent topics in Mark Avigan's work include Liver Disease Diagnosis and Treatment (22 papers), Drug-Induced Hepatotoxicity and Protection (20 papers) and Pharmacogenetics and Drug Metabolism (9 papers). Mark Avigan is often cited by papers focused on Liver Disease Diagnosis and Treatment (22 papers), Drug-Induced Hepatotoxicity and Protection (20 papers) and Pharmacogenetics and Drug Metabolism (9 papers). Mark Avigan collaborates with scholars based in United States, United Kingdom and Spain. Mark Avigan's co-authors include David Levens, Lanh Green, Ann Corken Mackey, Patricia A. Dinndorf, Leonard S. Bazar, Henry C. Krutzsch, Takeshi Tomonaga, Raúl J. Andrade, Neil Kaplowitz and Einar S. Björnsson and has published in prestigious journals such as Journal of Biological Chemistry, Genes & Development and Annals of Internal Medicine.

In The Last Decade

Mark Avigan

70 papers receiving 3.3k citations

Hit Papers

Case Definition and Phenotype Standardization in Drug-Ind... 2011 2026 2016 2021 2011 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Case Definition and Phenotype Standardization in Drug-Induced Liver Injury
    2011 713 citations Guruprasad P. Aithal, PB Watkins et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Avigan United States 28 969 966 938 620 562 71 3.5k
Marie‐Anne Loriot France 44 1.2k 1.2× 1.3k 1.4× 1.2k 1.2× 1.3k 2.1× 1.0k 1.8× 159 5.8k
Naomi Tanaka Japan 31 627 0.6× 965 1.0× 396 0.4× 750 1.2× 612 1.1× 135 3.3k
James P. Luyendyk United States 41 1.7k 1.7× 1.2k 1.3× 1.0k 1.1× 723 1.2× 1.0k 1.8× 115 4.9k
Wolfgang E. Thasler Germany 35 932 1.0× 1.6k 1.6× 348 0.4× 994 1.6× 1.1k 1.9× 131 4.3k
P. L. M. Jansen Netherlands 34 764 0.8× 1.0k 1.1× 467 0.5× 1.7k 2.7× 639 1.1× 79 3.8k
Jean‐Michel Fabre France 35 899 0.9× 464 0.5× 1.0k 1.1× 1.7k 2.7× 1.1k 1.9× 91 4.2k
Yasushi Matsuzaki Japan 34 714 0.7× 916 0.9× 275 0.3× 738 1.2× 617 1.1× 101 3.1k
Francisco Javier Cubero Spain 32 1.3k 1.3× 937 1.0× 381 0.4× 336 0.5× 793 1.4× 90 2.9k
Yves Horsmans Belgium 29 852 0.9× 401 0.4× 439 0.5× 396 0.6× 721 1.3× 93 2.3k
Stephen K. Durham United States 35 484 0.5× 1.1k 1.1× 519 0.6× 785 1.3× 337 0.6× 90 5.2k

Countries citing papers authored by Mark Avigan

Since Specialization
Citations

This map shows the geographic impact of Mark Avigan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Avigan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Avigan more than expected).

Fields of papers citing papers by Mark Avigan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Avigan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Avigan. The network helps show where Mark Avigan may publish in the future.

Co-authorship network of co-authors of Mark Avigan

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Avigan. A scholar is included among the top collaborators of Mark Avigan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Avigan. Mark Avigan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Willett, Rose, Volodymyr Tryndyak, J. Hanks, et al.. (2024). A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice. Toxicology and Applied Pharmacology. 491. 117046–117046. 1 indexed citations
3.
Halegoua‐DeMarzio, Dina, Huiman X. Barnhart, David E. Kleiner, et al.. (2024). Amiodarone and Dronedarone Causes Liver Injury with Distinctly Different Clinical Presentations. Digestive Diseases and Sciences. 69(4). 1479–1487. 1 indexed citations
4.
5.
Jones, S. Christopher, et al.. (2021). Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A Retrospective Case Series. Drug Safety. 44(12). 1365–1374. 13 indexed citations
6.
Wang, Tao, Matthew M. Yeh, Mark Avigan, Lorraine Pelosof, & Gerald M. Feldman. (2021). Deciphering the Dynamic Complexities of the Liver Microenvironment — Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI). The AAPS Journal. 23(5). 99–99. 1 indexed citations
7.
8.
Fontana, Robert J., Mark Avigan, Harry L.A. Janssen, et al.. (2019). Liver safety assessment in clinical trials of new agents for chronic hepatitis B. Journal of Viral Hepatitis. 27(2). 96–109. 11 indexed citations
9.
Aithal, Guruprasad P., PB Watkins, Raúl J. Andrade, et al.. (2011). Case Definition and Phenotype Standardization in Drug-Induced Liver Injury. Clinical Pharmacology & Therapeutics. 89(6). 806–815. 713 indexed citations breakdown →
10.
Weaver, Joyce, Mary E. Willy, & Mark Avigan. (2008). Informatic Tools and Approaches in Postmarketing Pharmacovigilance Used by FDA. The AAPS Journal. 10(1). 35–41. 35 indexed citations
11.
Colman, Eric, et al.. (2008). An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system. Pharmacoepidemiology and Drug Safety. 17(11). 1068–1076. 41 indexed citations
12.
Mackey, Ann Corken, et al.. (2007). Hepatosplenic T Cell Lymphoma Associated With Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition. 44(2). 265–267. 371 indexed citations
13.
Brinker, Allen, Andrew D. Mosholder, Stephanie D. Schech, Margaret Burgess, & Mark Avigan. (2007). Indication and Use of Drug Products Used to Treat Attention-Deficit/Hyperactivity Disorder: A Cross-Sectional Study with Inference on the Likelihood of Treatment in Adulthood. Journal of Child and Adolescent Psychopharmacology. 17(3). 328–333. 8 indexed citations
14.
Brinker, Allen, Stephanie D. Schech, Margaret Burgess, & Mark Avigan. (2007). An Observational Study of Cholecystectomy in Patients Receiving Tegaserod. Drug Safety. 30(7). 581–588. 2 indexed citations
15.
Sunitha, Iruvanti, et al.. (1999). A src-Related Kinase in the Brush Border Membranes of Gastrointestinal Cells Is Regulated by c-met. Experimental Cell Research. 250(1). 86–98. 11 indexed citations
16.
Avigan, Mark, et al.. (1998). FUSE-binding protein is developmentally regulated and is highly expressed in mouse and chicken embryonic brain. Neuroscience Letters. 252(3). 191–194. 16 indexed citations
17.
Bazar, Leonard S., et al.. (1995). Targeted Melting and Binding of a DNA Regulatory Element by a Transactivator of c-myc. Journal of Biological Chemistry. 270(14). 8241–8248. 64 indexed citations
18.
Sunitha, Iruvanti & Mark Avigan. (1994). A newly identified tyrosine kinase is preferentially expressed in the gastrointestinal tract. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1221(3). 348–352. 10 indexed citations
19.
Hoofnagle, Jay H., Kevin D. Mullen, Matthew Peters, et al.. (1987). Treatment of chronic delta hepatitis with recombinant human alpha interferon.. PubMed. 234. 291–8. 38 indexed citations
20.
Avigan, Mark, Kamal G. Ishak, Richard E. Gregg, & Jay H. Hoofnagle. (1984). Morphologic Features of the Liver in Abetalipoproteinemia. Hepatology. 4(6). 1223–1226. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marie‐Anne Loriot Breakdown of academic impact, for papers by Naomi Tanaka Breakdown of academic impact, for papers by James P. Luyendyk Breakdown of academic impact, for papers by Wolfgang E. Thasler Breakdown of academic impact, for papers by P. L. M. Jansen Breakdown of academic impact, for papers by Jean‐Michel Fabre Breakdown of academic impact, for papers by Yasushi Matsuzaki Breakdown of academic impact, for papers by Francisco Javier Cubero Breakdown of academic impact, for papers by Yves Horsmans Breakdown of academic impact, for papers by Stephen K. Durham
Rankless by CCL
2026